Autolus Therapeutics plc
| NASDAQ: AUTL | Healthcare / Biotechnology / United Kingdom |
| 3.89 | -0.1200 | -2.99% | Vol 773.47K | 1Y Perf 23.38% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 3.20 | ASK | 4.30 | ||
| Open | 4.04 | Previous Close | 4.01 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 8.60 | Analyst Rating | Strong Buy 1.14 | |
| Potential % | 121.08 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 48.28 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 44.99 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 70.90 | Earnings Rating | Sell | |
| Market Cap | 676.82M | Earnings Date | 2nd Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.23 | |
| Beta | 1.68 |
Today's Price Range 3.814.20 | 52W Range 1.604.83 | 5 Year PE Ratio Range -42.60-3.60 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -9.11% | ||
| 1 Month | 5.71% | ||
| 3 Months | 24.68% | ||
| 6 Months | 31.86% | ||
| 1 Year | 23.38% | ||
| 3 Years | -67.45% | ||
| 5 Years | -89.49% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -34.56 | |||
ROE last 12 Months | -88.77 | |||
ROA (5Y Avg) | -22.87 | |||
ROA last 12 Months | -63.50 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -71.48 | |||
Return on invested Capital Q | -20.24 | |||
Return on invested Capital Y | -13.91 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.00 | ||||
| 1.93 | ||||
| 131.49 | ||||
| - | ||||
| -2.90 | ||||
| -1.20 | ||||
| 1.93 | ||||
| 0.93 | ||||
| 163.58M | ||||
| Forward PE | -4.70 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.30 | ||||
| 5.50 | ||||
| 0.07 | ||||
| 0.09 | ||||
| -27.90 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -5 723.00 | ||||
| -5 476.20 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.37M | ||||
| 0.01 | ||||
| -11.66 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.24 | -0.26 | -8.33 |
| Q02 2023 | -0.22 | -0.26 | -18.18 |
| Q01 2023 | -0.28 | -0.23 | 17.86 |
| Q04 2022 | -0.31 | -0.23 | 25.81 |
| Q03 2022 | -0.46 | -0.47 | -2.17 |
| Q02 2022 | -0.42 | -0.46 | -9.52 |
| Q01 2022 | -0.51 | -0.41 | 19.61 |
| Q04 2021 | -0.49 | -0.51 | -4.08 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.25 | -4.17 | Negative |
| 12/2023 FY | -0.99 | -2.06 | Negative |
| 3/2024 QR | -0.23 | 0.00 | - |
| 12/2024 FY | -0.89 | -3.49 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.24 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 773.47K |
| Shares Outstanding | 173.99K |
| Shares Float | 66.12M |
| Trades Count | 6.84K |
| Dollar Volume | 3.07M |
| Avg. Volume | 703.95K |
| Avg. Weekly Volume | 453.76K |
| Avg. Monthly Volume | 1.04M |
| Avg. Quarterly Volume | 613.23K |
Autolus Therapeutics plc (NASDAQ: AUTL) stock closed at 3.89 per share at the end of the most recent trading day (a -2.99% change compared to the prior day closing price) with a volume of 773.47K shares and market capitalization of 676.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 298 people. Autolus Therapeutics plc CEO is Christian Itin.
The one-year performance of Autolus Therapeutics plc stock is 23.38%, while year-to-date (YTD) performance is 104.74%. AUTL stock has a five-year performance of -89.49%. Its 52-week range is between 1.6 and 4.83, which gives AUTL stock a 52-week price range ratio of 70.90%
Autolus Therapeutics plc currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 1.93, a price-to-sale (PS) ratio of 131.49, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -63.50%, a ROC of -71.48% and a ROE of -88.77%. The company’s profit margin is -%, its EBITDA margin is -5 476.20%, and its revenue ttm is $2.37 Million , which makes it $0.01 revenue per share.
Of the last four earnings reports from Autolus Therapeutics plc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. Autolus Therapeutics plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Autolus Therapeutics plc is Strong Buy (1.14), with a target price of $8.6, which is +121.08% compared to the current price. The earnings rating for Autolus Therapeutics plc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Autolus Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Autolus Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.39, ATR14 : 0.43, CCI20 : -24.19, Chaikin Money Flow : 0.46, MACD : 0.28, Money Flow Index : 56.96, ROC : -7.82, RSI : 52.89, STOCH (14,3) : 53.67, STOCH RSI : 0.09, UO : 63.69, Williams %R : -46.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Autolus Therapeutics plc in the last 12-months were:
Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.
CEO: Christian Itin
Telephone: +44 2038296230
Address: 58 Wood Lane, London W12 7RZ, , GB
Number of employees: 298
TipRanks News for AUTL
Wed, 29 Nov 2023 10:50 GMT Analysts Top Healthcare Picks: Autolus Therapeutics (AUTL), Amphastar Pharmaceuticals (AMPH)
- TipRanks. All rights reserved.
